Published in Curr Opin Hematol on July 01, 2013
Histone modifications predispose genome regions to breakage and translocation. Genes Dev (2015) 1.67
Quantitative detection of rare interphase chromosome breaks and translocations by high-throughput imaging. Genome Biol (2015) 0.81
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget (2016) 0.76
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol (2008) 6.90
The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07
A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A (2008) 4.45
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene (1997) 2.80
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol (2011) 1.95
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2002) 1.87
Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood (1997) 1.83
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol (1998) 1.68
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst (2008) 1.60
Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol (2008) 1.43
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol (2010) 1.31
Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood (2004) 1.26
What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia (2005) 1.22
Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol (2003) 1.21
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A (2010) 1.15
Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol (2004) 1.08
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res (2009) 1.07
Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem (2000) 1.05
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia (2011) 1.04
Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer (1998) 1.04
Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol (2008) 1.01
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. Blood (2012) 1.01
IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol (2009) 1.00
Anaplastic large-cell lymphoma. Semin Diagn Pathol (2011) 1.00
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol (2009) 0.98
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res (2008) 0.97
Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood (2011) 0.90
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma. Front Oncol (2012) 0.88
Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA. Oncogene (2010) 0.87
Inhibition of Rac controls NPM-ALK-dependent lymphoma development and dissemination. Blood Cancer J (2011) 0.84
Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal (2011) 0.84
The nucleophosmin-anaplastic lymphoma kinase oncogene interacts, activates, and uses the kinase PIKfyve to increase invasiveness. J Biol Chem (2011) 0.83
CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. Int J Oncol (2003) 0.83
Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics (2010) 0.80
Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol (2007) 0.78
Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells. Cancer Sci (2012) 0.77
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med (2005) 6.45
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature (2011) 5.20
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell (2006) 4.48
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst (2004) 4.07
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods (2008) 3.55
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest (2009) 3.34
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol (2004) 2.90
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
Geographic dependence, surveillance, and origins of the 2009 influenza A (H1N1) virus. N Engl J Med (2009) 2.85
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol (2013) 2.66
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood (2002) 2.57
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol (2003) 2.44
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood (2009) 2.36
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 2.36
A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk. Cell (2013) 2.28
Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. Oncology (Williston Park) (2012) 2.23
Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park) (2012) 2.18
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood (2005) 2.15
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood (2013) 2.14
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol (2006) 2.09
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica (2007) 2.05
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood (2011) 2.04
Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst (2006) 1.99
Patterns of evolution and host gene mimicry in influenza and other RNA viruses. PLoS Pathog (2008) 1.96
Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol (2011) 1.95
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood (2005) 1.92
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood (2012) 1.88
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol (2005) 1.88
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2002) 1.87
Plasma cells require autophagy for sustainable immunoglobulin production. Nat Immunol (2013) 1.85
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol (2005) 1.82
Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. J Immunol (2005) 1.73
Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. Thromb Haemost (2003) 1.73
Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med (2004) 1.72
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood (2007) 1.67
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
Lymphoblastic lymphoma. Crit Rev Oncol Hematol (2011) 1.65
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res (2010) 1.62
Bone marrow as an alternative site for islet transplantation. Blood (2009) 1.61
Heart and skeletal muscle inflammation of farmed salmon is associated with infection with a novel reovirus. PLoS One (2010) 1.58
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood (2008) 1.55
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med (2009) 1.54
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood (2011) 1.53
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest (2006) 1.51
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood (2011) 1.51
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.51
Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma (2013) 1.49
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood (2011) 1.49
STAT3: a multifaceted oncogene. Proc Natl Acad Sci U S A (2006) 1.48
In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A (2008) 1.48
Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma (2007) 1.46
Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma (2010) 1.44
Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc (2011) 1.44
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol (2005) 1.44
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood (2008) 1.43
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas. Am J Clin Pathol (2005) 1.43
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood (2011) 1.42
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 1.40
Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity. Eur J Immunol (2014) 1.39
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood (2009) 1.36
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med (2009) 1.35
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood (2013) 1.34